TITLE:
Evaluation of Efficacy and Safety of Platelet-Rich Plasma Eye Drops in Patients with Dry Eye Syndrome
AUTHORS:
Li Huang, Bin Wu, Jing Mao, Liping Peng, Xiaoqin Liu, Min Wang
KEYWORDS:
Sjogren’s Syndrome, Dry Eye, Platelet-Rich Plasma, Eye Drops, Efficacy
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.13 No.6,
June
4,
2025
ABSTRACT: Objective: To explore the clinical efficacy and safety of autologous platelet-rich plasma (PRP) eye drops in treating moderate to severe dry eye syndrome (SS). Method: A prospective randomized controlled study was conducted, including 60 patients with SS and moderate to severe dry eye syndrome admitted to the First People’s Hospital of Jingzhou from May 2024 to May 2025. The patients were randomly divided into the PRP group (n = 30) and the control group (n = 30). The PRP group received autologous PRP eye drops, while the control group used 0.3% sodium hyaluronate eye drops, both administered three times daily for one month. The primary outcome measures included changes in the Schirmer test, tear film break-up time (BUT), and corneal conjunctival fluorescein staining (CFS) scores before and after treatment, along with recording any adverse reactions. Results: After treatment, the PRP group showed significantly better Schirmer test values (6.8 ± 1.5 mm vs 4.5 ± 1.2 mm) and BUT (8.2 ± 1.2s vs 5.0 ± 0.9 s) compared to the control group, with a significant decrease in CFS scores (3.1 ± 0.8 vs 5.2 ± 1.3) (all P 0.05). Conclusion: Autologous PRP eye drops can effectively improve dry eye symptoms in SS patients, promote ocular surface repair, and have good safety and clinical application value.